Moreover, the 36-month beta value for KOD is 2.06. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for KOD is 48.64M and currently, short sellers hold a 3.51% of that float. On February 04, 2025, KOD’s average trading volume was 456.52K shares.
KOD) stock’s latest price update
Kodiak Sciences Inc (NASDAQ: KOD)’s stock price has gone decline by -9.06 in comparison to its previous close of 6.40, however, the company has experienced a -22.81% decrease in its stock price over the last five trading days. prnewswire.com reported 2025-01-07 that PALO ALTO, Calif., Jan. 7, 2025 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.
KOD’s Market Performance
KOD’s stock has fallen by -22.81% in the past week, with a monthly drop of -41.51% and a quarterly rise of 47.34%. The volatility ratio for the week is 8.72% while the volatility levels for the last 30 days are 10.27% for Kodiak Sciences Inc The simple moving average for the last 20 days is -25.86% for KOD’s stock, with a simple moving average of 34.42% for the last 200 days.
Analysts’ Opinion of KOD
Many brokerage firms have already submitted their reports for KOD stocks, with Jefferies repeating the rating for KOD by listing it as a “Buy.” The predicted price for KOD in the upcoming period, according to Jefferies is $20 based on the research report published on December 09, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see KOD reach a price target of $3. The rating they have provided for KOD stocks is “Neutral” according to the report published on September 05th, 2024.
Goldman gave a rating of “Sell” to KOD, setting the target price at $2 in the report published on December 11th of the previous year.
KOD Trading at -27.51% from the 50-Day Moving Average
After a stumble in the market that brought KOD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.83% of loss for the given period.
Volatility was left at 10.27%, however, over the last 30 days, the volatility rate increased by 8.72%, as shares sank -32.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.83% upper at present.
During the last 5 trading sessions, KOD fell by -22.81%, which changed the moving average for the period of 200-days by +49.61% in comparison to the 20-day moving average, which settled at $7.85. In addition, Kodiak Sciences Inc saw -41.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KOD starting from BORGESON JOHN A., who sale 2,874 shares at the price of $2.75 back on Jun 17 ’24. After this action, BORGESON JOHN A. now owns 182,164 shares of Kodiak Sciences Inc, valued at $7,904 using the latest closing price.
BORGESON JOHN A., the of Kodiak Sciences Inc, sale 1,558 shares at $2.92 during a trade that took place back on Jun 12 ’24, which means that BORGESON JOHN A. is holding 179,544 shares at $4,549 based on the most recent closing price.
Stock Fundamentals for KOD
The total capital return value is set at -0.59. Equity return is now at value -78.57, with -41.64 for asset returns.
Based on Kodiak Sciences Inc (KOD), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -1.63.
Currently, EBITDA for the company is -259.02 million with net debt to EBITDA at 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.42.
Conclusion
To wrap up, the performance of Kodiak Sciences Inc (KOD) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
